General
Preferred name
PIPOBROMAN
Synonyms
Abbott brand of pipobroman ()
Vercyte ()
A-8103 ()
Amedel ()
Pipobroman ()
PipobromanAmedelVercyte1,4-Bis(3-bromopropionyl)piperazineN,N'-Bis(3-bromopropionyl)piperazineA 1803A-8103NSC-25154WLN: T6N DNTJ AV2E DV2EPiperazine, 1,4-bis(3-bromo-1-oxopropyl)- ()
PB, Vercyte ()
NSC-25154 ()
P&D ID
PD000989
CAS
54-91-1
Tags
available
drug
Approved by
FDA
First approval
1966
Drug indication
Polycythemia vera
Refractory chronic myeloid leukaemia
Drug Status
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
This is a DNA alkylating agent.
(GtoPdb)
PRICE
29
DESCRIPTION
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al[1].
DESCRIPTION
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET).
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NIH Approved Oncology Drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Molecular Weight
353.96
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
0
cLogP
1.23
TPSA
40.62
Fraction CSP3
0.8
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
DNA alkylator/crosslinker
DNA alkylator
DNA/RNA Synthesis
Indication
polycythemia vera, thrombocythemia
MOA
DNA alkylating agent
ATC
L01AX02
Therapeutic Class
Anticancer Agents
Pathway
Cell Cycle/DNA Damage
DNA Damage/DNA Repair
Source data

